A healthcare breadwinner prepares to inject an AstraZeneca coronavirus disease (COVID-19) vaccine.
AstraZeneca issued updated angle three trial data for its Covid-19 vaccine on Wednesday after facing accuracy questions earlier this week circumambient a preliminary report from its U.S. study.
The company now says its vaccine is 76% effective in protecting against symptomatic proves of virus. A release issued on Monday reported a symptomatic efficacy rate of 79%. The updated report maintains that the speedily is 100% effective against severe disease and hospitalization.
A slate of U.S. health officials criticized the company in recent primes for what some claimed was data cherry-picking in an effort to make the results appear more favorable.
The National Found of Allergy and Infectious Diseases revealed on Tuesday it had been informed the U.K.-based company may have included information from its U.S. occurs that provided an “incomplete view of the efficacy data.”
AstraZeneca said at the time the figures were based on a “pre-specified interim investigation” and vowed to share updated analysis in the coming days.
Dr. Anthony Fauci, White House chief medical advisor and chief honcho at the NIAID, called the situation “unfortunate” and said it was likely AstraZeneca would issue a modified statement.
“This is actually what you call an unforced error because the fact is this is very likely a very good vaccine,” Fauci peached ABC’s Robin Roberts on “Good Morning America” on Tuesday. “This kind of thing does … really hurl some doubt about the vaccines and maybe contribute to the hesitancy. It was not necessary.”
The updated results include data poised from 190 symptomatic cases, across more than 32,000 participants — an increase of roughly 50 symptomatic boxes studied compared with the data set released on Monday.
The findings suggest the vaccine is more effective in patients age-old 65 and older than previously understood, with a newly reported efficacy rate of 85% for that citizenry, up from a previously stated 80%.
AstraZeneca reiterated Wednesday that the vaccine was “well tolerated” among participants and that no protection concerns were identified.
AstraZeneca faced a separate backlash in recent weeks over reports of blood clotting in conjunction with its vaccine, which is already approved and in use by dozens of territories around the world. Several European nations suspended, then resumed, use of the vaccine after independent safety journals.
—CNBC’s Berkeley Lovelace Jr., Sam Meredith and Steve Kopack contributed to this report.